Travere Therapeutics free cash flow TVTX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2012.

Travere Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY25, it was $14.2M.

Free cash flow over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Free cash flow	On a year earlier	Last 12 months
Q3 FY25	Sep 30, 2025	$14.2M	n/a	n/a
Q3 FY24	Sep 30, 2024	−$42.5M	n/a	−$272.3M
Q2 FY24	Jun 30, 2024	−$40.3M	n/a	−$289M
Q1 FY24	Mar 31, 2024	−$119M	n/a	−$317.9M
Q4 FY23	Dec 31, 2023	−$70.5M	n/a	−$280.7M
Q3 FY23	Sep 30, 2023	−$59.1M	n/a	−$264.9M
Q2 FY23	Jun 30, 2023	−$69.3M	n/a	−$245.3M
Q1 FY23	Mar 31, 2023	−$81.7M	n/a	−$212.8M
Q4 FY22	Dec 31, 2022	−$54.7M	n/a	−$186.5M
Q3 FY22	Sep 30, 2022	−$39.5M	−225%	−$158.8M
Q2 FY22	Jun 30, 2022	−$36.8M	−676%	−$87.6M
Q1 FY22	Mar 31, 2022	−$55.5M	n/a	−$44.4M

Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.

Company	Free cash flow yield
TVTXTravere Therapeutics	n/m
INDVIndivior Pharmaceuticals	−2.7%
ARQTArcutis Biotherapeutics	1.0%
LQDALiquidia	3.9%
KNSAKiniksa Pharmaceuticals International	3.1%
LGNDLigand Pharmaceuticals	2.2%
OGNOrganon	15.7%
AMRXAmneal Pharmaceuticals	2.0%
ALKSAlkermes plc.	3.0%
NRIXNurix Therapeutics	13.4%
TGTXTG Therapeutics	0.2%
Peer median	2.6%

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.